15 November 2016
A comprehensive review published in the Journal of Parkinson’s Disease confirms that people living with Parkinson’s disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls. It concludes that health professionals should be confident about prescribing physical activity to improve the health and quality of life of PD patients.
12 July 2016
Parkinson’s disease (PD) is the second most common neurodegenerative disorder that causes a range of motor and non-motor symptoms. During the course of the disease, dopamine (DA)-producing neurons are lost and bundles of proteins known as Lewy bodies (LBs) form in the brain. A study reported in the Journal of Parkinson’s Disease provided molecular evidence that the FDA-approved leukemia drug nilotinib may restore brain dopamine and reduce toxic proteins associated with LB formation in PD and dementia patients.
21 June 2016
We are pleased to inform you that the Journal of Parkinson’s Disease (JPD) now has its own Twitter account: @journal_PD.
12 April 2016
Accurate diagnosis of Parkinson’s disease, and the related disease “dementia with Lewy bodies,” can be difficult in the early stages of both conditions. While brain biopsies can be more accurate, the risk of complications has been considered too high. New research published in the Journal of Parkinson’s Disease indicates that a biopsy of the submandibular gland can help identify the same pathology that is seen in the brain, providing some of the increased accuracy of brain biopsy, but not the increased risk.
31 March 2016
The Journal of Parkinson’s Disease (JPD) is proud to announce the launch of the Parkinson’s Disease Funding Analyzer (PDFA) on the JPD website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the Parkinson’s disease (PD) research community.
29 March 2016
As stem cell-based therapies are moving rapidly towards clinical trials, treatments for Parkinson’s Disease (PD), an incurable condition, may be on the horizon. A recent announcement of a Phase I/IIa clinical trial involving transplantation of stem cells into the first human subjects has raised hope among patients and sparked discussions in the research community. In a commentary published in the Journal of Parkinson’s Disease, authors propose five key questions that should be addressed as this trial begins.
18 March 2016
Cognitive impairment could affect the conversational ability of people with Parkinson’s more than physical speech problems - according to research from the University of East Anglia (UEA) and the University of Aberdeen.
A new study published today is the first to assess the extent to which a patient’s ability to think quickly forms a barrier to communication – rather than experiencing physical speech problems.
17 February 2016
Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.
8 January 2016
Lewy bodies and Lewy neurites are found in the brains of Parkinson’s disease (PD) patients. They consist primarily of fibrils of the protein alpha-synuclein (α-Syn), which self-assembles into fibrils in vitro. If introduced into the human body, these seeds can act as prions and trigger the formation of toxic protein deposits. Because α-Syn fibrils are often used in research, it is important that they are not accidentally transferred to humans or cell cultures. Researchers reporting in the Journal of Parkinson’s Disease describe three cleaning procedures that effectively remove and disassemble these α-synuclein seeds.
4 January 2016
Recent evidence has shown a greater risk of dementia, in particular Alzheimer’s disease (AD), in individuals using anticholinergic medications regularly. These drugs are widely used by older adults to treat bladder dysfunction, mood, and pain, and many of them are available without prescription. Since these drugs are often used to treat both motor symptoms and non-motor symptoms in patients with Parkinson’s Disease (PD), there is concern for increased risk of dementia. Contrary to expectations, a study in the current issue of the Journal of Parkinson’s Disease determined that the cognitive performance of PD patients taking anticholinergic medications did not differ from those who did not.